242 related articles for article (PubMed ID: 28871635)
1. Fatty acid synthase as a potential therapeutic target in feline oral squamous cell carcinoma.
Walz JZ; Saha J; Arora A; Khammanivong A; O'Sullivan MG; Dickerson EB
Vet Comp Oncol; 2018 Mar; 16(1):E99-E108. PubMed ID: 28871635
[TBL] [Abstract][Full Text] [Related]
2. Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment.
DiBernardi L; Doré M; Davis JA; Owens JG; Mohammed SI; Guptill CF; Knapp DW
Prostaglandins Leukot Essent Fatty Acids; 2007 Apr; 76(4):245-50. PubMed ID: 17383864
[TBL] [Abstract][Full Text] [Related]
3. Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma.
Brown ME; Bear MD; Rosol TJ; Premanandan C; Kisseberth WC; London CA
BMC Vet Res; 2015 Aug; 11():206. PubMed ID: 26272737
[TBL] [Abstract][Full Text] [Related]
4. A novel MCT1 and MCT4 dual inhibitor reduces mitochondrial metabolism and inhibits tumour growth of feline oral squamous cell carcinoma.
Khammanivong A; Saha J; Spartz AK; Sorenson BS; Bush AG; Korpela DM; Gopalakrishnan R; Jonnalagadda S; Mereddy VR; O'Brien TD; Drewes LR; Dickerson EB
Vet Comp Oncol; 2020 Sep; 18(3):324-341. PubMed ID: 31661586
[TBL] [Abstract][Full Text] [Related]
5. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas.
Seguin F; Carvalho MA; Bastos DC; Agostini M; Zecchin KG; Alvarez-Flores MP; Chudzinski-Tavassi AM; Coletta RD; Graner E
Br J Cancer; 2012 Sep; 107(6):977-87. PubMed ID: 22892389
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of ubiquitin-specific protease 2a (USP2a), fatty acid synthase (FASN), and ErbB2 expression in oral squamous cell carcinomas.
da Silva SD; Cunha IW; Nishimoto IN; Soares FA; Carraro DM; Kowalski LP; Graner E
Oral Oncol; 2009 Oct; 45(10):e134-9. PubMed ID: 19362044
[TBL] [Abstract][Full Text] [Related]
7. Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype.
Kant S; Kumar A; Singh SM
Biochim Biophys Acta; 2014 Jan; 1840(1):294-302. PubMed ID: 24060750
[TBL] [Abstract][Full Text] [Related]
8. FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1.
Almeida LY; Moreira FDS; Santos GASD; Cuadra Zelaya FJM; Ortiz CA; Agostini M; Mariano FS; Bastos DC; Daher URN; Kowalski LP; Coletta RD; Graner E
Oral Dis; 2023 Mar; 29(2):649-660. PubMed ID: 34510641
[TBL] [Abstract][Full Text] [Related]
9. Investigation of immune cell markers in feline oral squamous cell carcinoma.
Sparger EE; Murphy BG; Kamal FM; Arzi B; Naydan D; Skouritakis CT; Cox DP; Skorupski K
Vet Immunol Immunopathol; 2018 Aug; 202():52-62. PubMed ID: 30078599
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer.
Bauerschlag DO; Maass N; Leonhardt P; Verburg FA; Pecks U; Zeppernick F; Morgenroth A; Mottaghy FM; Tolba R; Meinhold-Heerlein I; Bräutigam K
J Transl Med; 2015 May; 13():146. PubMed ID: 25947066
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro efficacy of zoledronate for treating oral squamous cell carcinoma in cats.
Wypij JM; Fan TM; Fredrickson RL; Barger AM; de Lorimier LP; Charney SC
J Vet Intern Med; 2008; 22(1):158-63. PubMed ID: 18289304
[TBL] [Abstract][Full Text] [Related]
12. Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma.
Martin CK; Dirksen WP; Shu ST; Werbeck JL; Thudi NK; Yamaguchi M; Wolfe TD; Heller KN; Rosol TJ
Oral Oncol; 2012 Jun; 48(6):491-9. PubMed ID: 22265717
[TBL] [Abstract][Full Text] [Related]
13. Anticancer properties of the fatty acid synthase inhibitor TVB-3166 on oral squamous cell carcinoma cell lines.
Aquino IG; Bastos DC; Cuadra-Zelaya FJM; Teixeira IF; Salo T; Coletta RD; Graner E
Arch Oral Biol; 2020 May; 113():104707. PubMed ID: 32197133
[TBL] [Abstract][Full Text] [Related]
14. Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.
Martin CK; Dirksen WP; Carlton MM; Lanigan LG; Pillai SP; Werbeck JL; Simmons JK; Hildreth BE; London CA; Toribio RE; Rosol TJ
Vet Comp Oncol; 2015 Sep; 13(3):203-17. PubMed ID: 23651067
[TBL] [Abstract][Full Text] [Related]
15. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines.
Hill TK; Davis AL; Wheeler FB; Kelkar SS; Freund EC; Lowther WT; Kridel SJ; Mohs AM
Mol Pharm; 2016 Mar; 13(3):720-8. PubMed ID: 26824142
[TBL] [Abstract][Full Text] [Related]
16. Nicotine induces oral dysplastic keratinocyte migration via fatty acid synthase-dependent epidermal growth factor receptor activation.
Wisniewski DJ; Ma T; Schneider A
Exp Cell Res; 2018 Sep; 370(2):343-352. PubMed ID: 29966661
[TBL] [Abstract][Full Text] [Related]
17. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model.
Carvalho MA; Zecchin KG; Seguin F; Bastos DC; Agostini M; Rangel AL; Veiga SS; Raposo HF; Oliveira HC; Loda M; Coletta RD; Graner E
Int J Cancer; 2008 Dec; 123(11):2557-65. PubMed ID: 18770866
[TBL] [Abstract][Full Text] [Related]
18. Effects of fatty acid synthase inhibitors on lymphatic vessels: an in vitro and in vivo study in a melanoma model.
Bastos DC; Paupert J; Maillard C; Seguin F; Carvalho MA; Agostini M; Coletta RD; Noël A; Graner E
Lab Invest; 2017 Feb; 97(2):194-206. PubMed ID: 27918556
[TBL] [Abstract][Full Text] [Related]
19. Histologic, immunohistochemical, and in situ hybridization study of myxoid stroma in feline oral squamous cell carcinoma.
Mineshige T; Tanaka Y; Watanabe K; Tagawa M; Tomihari M; Kobayashi Y
J Vet Med Sci; 2024 Mar; 86(3):258-265. PubMed ID: 38233195
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
Lupu R; Menendez JA
Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
